UltraThera is developing therapeutic ultrasound to restore brain function, with Alzheimer’s disease as the lead indication. We are at an early clinical stage with proof-of-concept safety using our 1st generation ISO13485 system.

We have developed a therapy that targets toxic amyloid and toxic tau, as well as restoring memory and other brain functions. Our preclinical data shows that our approach activates the brain’s natural immune response to clear amyloid and tau build-up, and leads to cognitive restoration by enhancing network connectivity.

We are in late-stage development of the 2nd generation UltraThera platform capable of delivering personalized ultrasound treatments across a range of neurological indications. The system is portable, non-invasive and can deliver transcranial ultrasound focally or in a scanning mode.

We are seeking investors for a founding round to advance our Dementia therapy program.